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ReceivedBackground: Patients with advancedmetastatic disease are often treated aggressively
withmultiple lines of chemotherapy, even in the lastmonth of life. The benefit of such an
approach remains uncertain. The objective of the study was to investigate whether Ruta
graveolens 9c homeopathic medicine can improve quality of life (QoL) and tumour pro-
gression in patients with advanced cancer.
Material and methods: This was a single-centre, open-label, uncontrolled, pilot study.
Patients (>18-years, life-expectancy ‡3 months, performance status £2) with locally-
advanced solid tumours or metastases, previously treated with all available standard
anti-cancer treatments were recruited. Oral treatment consisted of two 1-mL ampoules
of Ruta graveolens (9c dilution) given daily for a minimum of 8 weeks, or until tumour
and/or clinical progression. Primary outcome was QoL measured using the EORTC QLQ-
C30questionnaire. Secondaryoutcomemeasureswereanxiety/depressionmeasuredusing
the Hospital Anxiety and Depression Scale (HADS), WHO performance status (PS), tumour
progression assessed using RECIST criteria and tumour markers, survival and tolerance.
Results: Thirty-one patients were included (mean age: 64.3 years). Mean duration of
treatmentwas 3.3months (median: 2.1). QoL global health status improved significantly
between baseline and week 8 (P < 0.001) and week 16 (P = 0.035), but was at the limit of
significance (P = 0.057) at the end of the study. There was no significant change in anx-
iety/depression or PS during treatment. Ruta graveolens 9c had no obvious effect on
tumour progression.Median survival was 6.7months [95%CI: 4.8e14.9].Ruta graveolens
9c was well-tolerated.
Conclusion: Some patients treated with Ruta graveolens 9c had a transitory improve-
ment in QoL, but the effectiveness of this treatment remains to be confirmed in further
studies. Homeopathy (2014) 103, 232e238.
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The management of cancer has improved considerably
over the past decade. Thanks to therapeutic advances, sur-
vival rates have increased in patients with advanced meta-
static disease.1e3 For these patients, symptom control and
optimisation, and enhanced quality of life (QoL) are the
primary treatment goals. However, patients with
metastatic disease are often treated aggressively with
multiple lines of chemotherapy, even in the last month of
life.4 The benefit of such an approach remains uncertain,
and it is recognised that the level and duration of disease
control decrease with each successive treatment.5,6 In
addition, treatment-related toxicity has an adverse effect
on the QoL of cancer patients at the end of their life.
A recent European study in patients with different types
of cancer reported that up to one-third of patients use com-
plementary and alternative medicines (CAM) after a diag-
nosis of cancer.7 A similar level of use was reported in the
UK.8 A recent Canadian study reported high usage of CAM
by women with breast cancer, with as many as 80% using
complementary therapies.9
Among the different types of CAM available, studies in
Western Europe show that a large proportion of patients
(42e60%) use homeopathy.7,10,11 A number of studies
have suggested that some homeopathic medicines may
help prevent the side-effects of conventional therapies,
such as radiodermatitis caused by radiotherapy,12e14 and
nausea and stomatitis associated with
chemotherapy.12,15,16 An observational UK study
reported significantly improved QoL, assessed using the
EORTC QLQ-C30 questionnaire, in 59% of cancer pa-
tients treated with homeopathy, and 63% of these patients
also had reduced anxietyedepression (measured using the
Hospital Anxiety and Depression Scale: HADS).17 In par-
allel, a French study, involving 244 patients with cancer, re-
ported an improved general state in 97% of patients taking
CAM (60% used homeopathy).11 Rostock et al. also re-
ported significant improvement in QoL in cancer patients
who used homeopathy for 3 and 12 months, although
they failed to find any change in the level of anxiety or
depression.18
Ruta graveolens is a medicinal plant that contains rutin
as its main active component. In complementary medicine,
it has been used historically to treat a variety of inflamma-
tory conditions. Its use as an agent with potential anti-
tumour activity has been investigated in several in vitro
and in vivo studies in which Ruta graveolens has been stud-
ied either as an extract or as homeopathic dilutions.19e23 In
these studies, Ruta graveolens extract has been shown to
have cytotoxic and antiproliferative activity towards a
range of human and animal cancer-cell lines, and to delay
tumour progression and increase survival times in mouse
in vivo models.19,23 At homeopathic dilutions, ranging
from 6 to 200c, Ruta graveolens showed in vitro
cytotoxic activity when taken alone20,21 or when
combined with Calcarea phosphorica (phosphate of
lime)22; it has also reduced tumour progression in
tumour-xenografted mice.19 Furthermore, although clin-ical data are limited, complete tumour regression was re-
ported in six out of seven glioma patients treated with
Ruta graveolens 6c plus Calcarea phosphorica 3c.22
However, although most studies suggest that Ruta grave-
olens has a potential benefit, the levels of evidence remain
low. No randomised trial, to date, has shown clear improve-
ment in cancer symptoms and/or treatment toxicity.
In view of these preclinical data for Ruta graveolens and
the previously reported benefits of CAM on the QoL of
cancer patients, we carried out a pilot study to investigate
whether homeopathic treatment with Ruta graveolens 9c
increased the QoL of patients with advanced cancer and
in whom all conventional anti-cancer treatments had failed.
Our secondary objectives were to measure the evolution of
anxietyedepression, performance status, tumour response,
global survival, progression-free survival and tolerance.
Materialandmethods
Conduct of the study
This uncontrolled, pilot study was carried out between
May 2010 and September 2011 in the Medical Oncology
Department of Lyon University Hospital, France. The
study was approved by a regional ethics committee (Com-
ite de Protection des Personnes SUD-EST IV) and the
AFSSaPS (Agence Franc¸aise de Securite Sanitaire des Pro-
duits de Sante; ref: A100078-41). The study was conducted
in accordance with the Declaration of Helsinki and in
compliance with the International Conference on
Harmonization-Good Clinical Practice (ICH-GCP) guide-
lines and with local enforcement laws (Law no: 2004-800
of 6th August 2004, and Law no: 2004-806 of 9th August
2004). All patients provided documented informed consent
before their participation in the study and treatment.
Study participants
In this pilot study, it was planned to include a total of 30
patients with pathologically confirmed locally advanced or
metastatic solid cancers, in whom, all standard therapies
had failed.
Inclusion criteria were being aged >18 years; a life ex-
pectancy of $3 months; a WHO performance status (PS)
of #2; histologically proven and a locally advanced solid
tumour, not accessible to loco-regional curative treatment,
or metastatic cancer; a measurable lesion according to RE-
CIST criteria24; progressive disease at inclusion (i.e.
increased size of tumour lesions on imagery, and/or an
increased tumour marker previously correlated with
tumour mass, and/or the deteriorating clinical state of the
patient); radiological/imaging that evaluated tumour pro-
gression in the previous month; measurement of tumour
markers in the previous 2 weeks; patient capable of partici-
pating in the treatment follow-up; and a recognised method
of contraception during the study period.
Exclusion criteria included receiving an anti-cancer
treatment within the previous month or planned during
the study period; uncontrolled cerebral metastases or carci-
nomatous meningitis; concomitant treatment with immu-
nosuppressants (for instance corticosteroids) for >1Homeopathy
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Homeopweek; concomitant treatment with other alternative thera-
pies; participation in another clinical trial (except for an
observational study); patient of childbearing age and not
using approved contraception; a patient pregnant or breast-
feeding; or a serious psychiatric illness.Study treatment
The study consisted of giving Ruta graveolens, at 9c
dilution: this is a registered homeopathic medicine in
France, prepared by Boiron Laboratories according to Eu-
ropean Pharmacopoeia standards, and provided in 1-mL
ampoules. Oral treatment was started on day 1 (baseline)
at a dose of two ampoules/day: one in the morning and
one in the evening, and taken for a minimum of 8 weeks.
All patients continued treatment until there was tumour
(RECIST) and/or clinical progression, which was defined
as the end of study (EOS) (Figure 1).Data collected
To document the status of pre-baseline disease progres-
sion, according to RECIST criteria,24 all patients had un-
dergone appropriate radiological/imaging and
measurement of serum tumour markers within the previous
month. The sociodemographic characteristics of the study
population were recorded at baseline (day 1). The study’s
protocol and timeline for collection of data are summarised
in Figure 1.
The following data were collected on day 1 and at week
8, and also at weeks 16, 28, 40 and 52 from patients where
treatment was continued beyond week 8. (i) QoL was as-
sessed using the EORTC QLQ-C30 questionnaire, which
includes five functional scales, three symptomatic scales,
six single scales, and the HRQOL-scale. (ii) Anxiety and
depression were measured using the HADS, which pro-
vides a global score of emotional wellbeing and has anxietyFigure 1 Study
athyand depressive sub-elements. (iii) Patient autonomy was
measured using WHO PS. (iv) Tumour response was as-
sessed by imagery (radiography, CAT scans or MRI) using
RECIST 1.1 criteria24 and defined as a complete response,
a partial response, stable disease, or as progressive disease,
or assessed by measuring tumour markers (CA15-3, ACE,
CA19-9, CA125, PSA and NSE).21 If disease progression
was detected at any point, the patient was informed and
it was suggested he stops homeopathic treatment. Alterna-
tive management was started, as decided by the patient and
the oncologist in charge.
Physical examination, haematological investigations
and assessment of tumour markers were carried out on
day 1, at week 4, and then at regular 4-weekly intervals
thereafter until the EOS.Primary evaluation criterion
The primary objective of our study was to measure the
evolution of QoL during treatment and at the EOS using
the EORTC QLQ-C30 auto-questionnaire.Secondary evaluation criteria
The secondary objectives were to measure: (i) the evolu-
tion of anxietyedepression (HADS); (ii) the evolution of
PS; (iii) tumour response; (iv) global survival (number of
weeks/months between inclusion in the study and death
of the patient); (v) survival without disease progression;
and (vi) tolerance to Ruta graveolens 9c.Tolerance
All adverse events (AEs) and serious AEs that occurred
during the study were recorded and evaluated using Na-
tional Cancer Institute criteria (version 4). Their relation-
ship to study treatment was assessed.protocol.
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Statistical analyses
Continuous variables are expressed as their mean, me-
dian, standard deviation (SD), or minimum and maximum.
Discrete variables are expressed as group size, percentage
and 95% confidence intervals (95%CI). The evolution of
variables measured at repeated intervals is represented as
means  SD and percentages. The two global criteria,
QoL and anxietyedepression, were compared using the
non-parametricWilcoxon’s test. Comparisons were carried
out between day 1 and the EOS, and between day 1 and
weeks 8 and 16. If there were missing data, analysis took
into account the last evaluation available according to the
last-observation-carried-forward (LOCF) method. Contin-
uous variables were compared with Wilcoxon’s test and
discrete variables with the chi2 test. The chi2 test was also
used to compare the evolution of RECIST criteria. All tests
were performed with an alpha-risk fixed at 5%, with the
level of statistical significance set at P < 0.05. All statistical
analyses were carried out using R2.14 software.Results
Description of the study population at baseline
A total of 31 patients (7 males, 24 females) with a mean
age of 64.3 years (range: 44e87 years) were included in theTable 1 Baseline characteristics of the study population
Characteristics at inclusion (n = 31) Mean [range] or n (%)
Age (years) 64.3 [44e87]
Weight (kg) 62.3 [44e116]
Tumour type
Breast 9 (29%)
Kidney 5 (16%)
Ovary 4 (13%)
Colo-rectal 3 (10%)
Lung 2 (6%)
Prostate 2 (6%)
Pancreas 1 (3%)
Stomach 1 (3%)
Endometrium 1 (3%)
Peritoneum 1 (3%)
Appendix 1 (3%)
Quality of life [0e100], (n = 30) 43.6 [0e66.7]
HADS (n = 30)
Global score [0e42] 17.7 [6e29]
Normal state 9 (30%)
Emotional unbalance 21 (70%)
Anxiety sub-score [0e21] 9.1
Certain [>10] 10 (33.3%)
Uncertain [8e10] 11 (36.7%)
Normal [<8] 9 (30%)
Depression sub-score [0e21] 8.5
Certain [>10] 8 (26.6%)
Uncertain [8e10] 11 (36.7%)
Normal [<8] 11 (36.7%)
Performance status (PS) (n = 31)
0 6 (19.3%)
1 19 (61.3%)
2 6 (19.4%)
Morphological status*(n = 31)
Stable 11 (35.5%)
Progressive 20 (64.5%)
* Morphological status at baseline was established using RECIST
criteria. Patients with morphological stability assessed by imagery
at baseline also had a tumour marker increase and/or disease-
related symptoms increase.study. The baseline characteristics of these patients are
summarised in Table 1. Advanced or treatment-refractory
breast cancer was the most common type of tumour
(29%), followed by renal cancer (16%) and ovarian cancer
(13%). As determined by pre-study and baseline tumour
data, assessed using RECIST criteria: 64.5% of patients
had morphological progression, and 35.5% had morpho-
logical stability at inclusion but had increased tumour
markers and/or disease-related symptoms. Most patients
maintained normal or almost normal activity according to
their PS (80.6% had PS # 1). The mean score for QoL at
inclusion was 43.6 (range: 0e66.7) and the mean score
for anxietyedepression (HADS) was 17.7 (range: 6e29)
(Table 1). Twenty-one patients (70%) had a HADS score
of $15, indicating emotional disturbance. For the HADS
anxietyedepression subscores, if ‘uncertain’ was included
as an affirmative response for assessment of anxiety/
depression, 70% of patients were anxious and 63% were
depressed (Table 1).Primary evaluation criterion
QoL: Twenty-four of the 31 patients (77.4%) were
included in the final analysis of QoL. One patient was
excluded as he did not complete any of the questionnaires
and six were excluded as they only completed one ques-
tionnaire. In these patients, early symptomatic progression
of the tumour led to the EOS. For the 24 patients analysed,
EORTC QLQ-C30 scores were available from baseline un-
til week 8, with data for week 16 available for nine patients.
When QoL status was compared between baseline and
week 8 the difference was statistically significant
(P < 0.001) (Table 2). For patients with QoL measured at
week 16, a significant improvement was also found
(P = 0.035). Furthermore, in each case, the mean improve-
ment from baseline was >10 points, which translates into a
meaningful clinical improvement.25 For the whole study
cohort, there was a trend towards improved QoL (global
health status) from inclusion until the EOS, although this
was not statistically significant (P = 0.057).Secondary evaluation criteria
Anxiety/depression: There was no significant difference
in the HADS global score or subscores for anxie-
tyedepression between inclusion and weeks 8, 16 and
the EOS (data not shown).
Index of performance status: There was no significant
change in PS during treatment (Table 3). At week 8, three
patients had improved PS while receiving Ruta graveolens
9c, and a similar number after 16 weeks of treatment. How-
ever, the majority of patients had no change or deteriora-
tion in PS during the study.
Tumour response: For the complete patient cohort, treat-
ment with Ruta graveolens 9c had no significant effect on
tumour response, assessed using RECIST criteria and by
measuring tumour markers. As part of our planned ana-
lyses, responses in patients were stratified according to
their morphological status at baseline (i.e. whether they
showed morphological stability or progression comparedHomeopathy
Table 2 Evolution of quality of life (QoL) score (global health
status) with Ruta graveolens 9c treatment
Assessment Baseline
(n = 24)
Week 8
(n = 24)
Week 16
(n = 9)
End of study
(n = 24)
QL2 score
Mean [SE] 42 [16.9] 55.2 [18.5] 55.6 [22.2] 49.6 [21.4]
P < 0.001* P = 0.035* P = 0.057
* Significant using the Wilcoxon test.
Figure 2 Presence ofmorphologic stability (tumour response) as-
sessed by imagery (RECIST criteria) up to week 28 in three
groups of patients: those with morphologic stability at inclusion
(n = 10), those with morphologic progression at inclusion
(n = 20) and all patients (n = 30).
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Homeopto pre-study evaluations). Of the 10 patients who showed
morphological stability assessed by imagery at baseline,
50% were stable after 8 weeks of treatment, 40% at week
16 and 20% at week 28 (Figure 2). Of the 20 patients
with morphological progression, assessed by imagery at
baseline, only one (5%) remained stable after 8 weeks of
treatment (Figure 2). The mean duration of morphologic
stability was 5.3 months.
Overall survival and survival without disease progres-
sion: Median overall survival was 6.7 months [95%CI:
4.8e14.9], median progression-free survival (clinical, bio-
logical or RECIST criteria) was 1.9 months [95%CI:
1.8e2.2] and median survival without any deterioration
in QoL (additional cancer treatment, and/or hospitalisa-
tion, and/or 20% decrease in QoL score) was 2.2 months
[95%CI: 2.0e3.9].
Tolerance: Mean duration of treatment was 3.3 months
(median: 2.1; range: 0.4e11), during which Ruta graveo-
lens 9c was well-tolerated. A total of 257 AEs were re-
ported in the 31 patients (Table 4). Twenty-eight patients
(90%) had at least one AE, with an average of nine AEs
per patient. The most frequent AEs reported during the
study were abdominal pain (10.9%), fatigue (10.5%),
musculoskeletal pain (10.5%) and headaches (4.7%).
Seven serious AEs were also reported, all related to the dis-
ease. None of the AEs or serious AEs was considered to be
directly related to treatment with Ruta graveolens 9c.Table 4 Treatment-emergent adverse events (AEs) occurring in
the study population (n = 31)
Most common adverse event n (%)
Abdominal pain 28 (10.9)
Fatigue 27 (10.5)
Musculoskeletal pain 27 (10.5)
Headache 12 (4.7)
Dyspnoea 9 (3.5)
Loss of appetite 8 (3.1)
Diarrhoea 7 (2.7)
Nausea 7 (2.7)
Constipation 6 (2.3)
AE $ grade 3 Event (n; grade) Patients (n)Discussion
This is the first study in Europe to report the usage of a
homeopathic medicine given to a well-described cohort of
patients with end-stage cancer. Our data suggest that pa-
tients treated with Ruta graveolens 9c experienced signifi-
cant and clinically meaningful improvements in QoL after
8 weeks of use, which was sustained over 16 weeks of treat-
ment (Table 2). However, no significant improvements in
secondary QoL assessments (HADS) were observed, and
improvements in PS during treatment were seen in only a
few patients (Table 3).Table 3 Evolution of performance status (PS) during Ruta
graveolens 9c treatment
PS change from
baseline (n = 31)
Week 8
(n = 25)
Week 16
(n = 9)
End of study
(n = 29)
Improvement 3 (12%) 3 (33%) 2 (7%)
No change 13 (52%) 3 (33%) 11 (38%)
Deterioration 9 (36%) 3 (33%) 16 (55%)
athyTaken as a whole, these results support those of previous
authors who have shown that homeopathic treatment can
improve QoL or general state in cancer patients.11,17,18
However, in concordance with the report of Frenkel,26 we
found no specific anti-tumour effects from this homeopath-
ic medicine, despite the promising profile of Ruta graveo-
lens in vitro and in experimental animals.19e23
There are three approaches to the treatment of patients
with end-stage cancer: palliative chemotherapy, aimed at
improving symptoms and postponing future symptom
development; palliative radiotherapy; or best supportive
care, aimed at improving or maintaining QoL. The pa-
tient’s choice of therapeutic approach is strongly influ-
enced by their inner perceptions of treatment, even
before discussing it with their oncologist.27 Many studies
show that end-stage cancer patients are ready to accept
the major toxicities associated with chemotherapy for
only small therapeutic benefits,27e29 although the
minimum survival benefit after accepting toxic
chemotherapy varies extensively from one patient to
another.30 Treatment refusal and the initiation of best sup-
portive care may, however, be beneficial to some patientsBowel obstruction 2; grade 3 2
Cholestasis 2; grade 3 1
Cytolysis 2; grade 3 1
Dysphagia 1; grade 3 1
Dyspnoea 1; grade 3 1
Constipation 1; grade 3 1
Malnutrition 1; grade 3 1
Abdominal pain 1; grade 3 1
Musculoskeletal pain 1; grade 3 1
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and could avoid the temptation of undertaking yet another
line of futile and toxic chemotherapy.
Several hypotheses can be proposed to explain the
improved QoL reported by our patients. First, a placebo ef-
fect cannot be discounted. However, in a review of rando-
mised placebo-controlled trials in cancer patients,
Chvetzoff and Tannock reported that there was limited
improvement in patients receiving a placebo and that pla-
cebo effects on QoL and PS were relatively rare.31 Thus,
the significant improvement in QoL seen in our patients
seems unlikely to be due to a placebo effect.
The second hypothesis is that improved QoL was caused
by the specificmanagement and attention paid to the patients
during this study. We feel that this is unlikely as, throughout
this study, patient management within the framework of
routine hospital carewas unchanged, with no particular extra
attention given to the patients under study.
The third hypothesis is that it could be due to changing to
best supportive care following cessation of specific cancer
therapies. It is well recognised that chemotherapy-related
toxicities greatly influence the patients’ experience and
negatively impact on QoL,32,33 and that QoL may
improve following treatment cessation. We cannot
exclude this phenomenon from our study.
The fourth hypothesis is that improvements in QoL
could be a result of natural fluctuations in the course of
the disease (spontaneous tumour regression).31 This is un-
likely as the majority of patients had morphological pro-
gression at baseline, with the best response being short-
term stability rather than regression.
Finally, we cannot exclude the possibility that the
improved QoL observed with Ruta graveolens 9c repre-
sented a genuine effect. Indeed, the improvements seen
(>10 points improvement in the QoL score) suggest that
this is a small, but clinically meaningful outcome. Further-
more, our study’s concept and Ruta graveolens 9c treat-
ment itself were both received favourably by the patients
and the clinicians involved. In part because of the paucity
of treatment-related AEs, compliance with treatment was
good. Indeed, 20% of patients (5/30) chose to continue
Ruta graveolens 9c treatment at their own request, despite
tumour progression, for a mean period of 6e36 weeks
beyond the EOS.
Our study has several limitations. The main limitations
are the small population size and the lack of a comparative
control group. Furthermore, there was also no control for
other medications or for medication changes that could
have had a significant impact on QoL. It should be pointed
out that this was only a pilot study to test a hypothesis, and
that larger randomised, controlled trials are necessary to
confirm a benefit of Ruta graveolens 9c in this clinical sit-
uation.Conclusion
Patients with metastatic disease are often treated aggres-
sively with multiple lines of toxic chemotherapy, even in
the last month of life. Ruta graveolens 9c may benefit pa-
tients with heavily-pretreated advanced cancer in terms ofQoL. However, no significant effect was observed on
tumour progression.
In light of our data and the limitations of this pilot study,
further studies are planned to evaluate the role of homeo-
pathic treatments in the management of patients with ter-
minal cancer as an alternative to conventional care, when
all standard cancer therapies have failed.
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